Peter E. Glennon

1.7k total citations
18 papers, 1.3k citations indexed

About

Peter E. Glennon is a scholar working on Molecular Biology, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Peter E. Glennon has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Cardiology and Cardiovascular Medicine and 6 papers in Physiology. Recurrent topics in Peter E. Glennon's work include Melanoma and MAPK Pathways (4 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and Nitric Oxide and Endothelin Effects (3 papers). Peter E. Glennon is often cited by papers focused on Melanoma and MAPK Pathways (4 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and Nitric Oxide and Endothelin Effects (3 papers). Peter E. Glennon collaborates with scholars based in United Kingdom, United States and Canada. Peter E. Glennon's co-authors include Marie A. Bogoyevitch, Peter H. Sugden, Angela Clerk, Monica Andersson, P H Sugden, Stephen J. Fuller, Antigone Lazou, C. J. Marshall, Peter J. Parker and Graham J. Sale and has published in prestigious journals such as Journal of Biological Chemistry, Circulation and Circulation Research.

In The Last Decade

Peter E. Glennon

17 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter E. Glennon United Kingdom 10 744 710 395 255 159 18 1.3k
Pamela C. Powell United States 19 635 0.9× 438 0.6× 239 0.6× 80 0.3× 151 0.9× 32 1.1k
Takehiko Yamada Japan 14 708 1.0× 490 0.7× 109 0.3× 83 0.3× 149 0.9× 30 1.1k
Masashi Namba Japan 14 310 0.4× 277 0.4× 287 0.7× 162 0.6× 89 0.6× 46 879
Daniel Walcher Germany 19 330 0.4× 664 0.9× 411 1.0× 56 0.2× 175 1.1× 44 1.5k
L Simonet United States 13 325 0.4× 342 0.5× 271 0.7× 94 0.4× 178 1.1× 22 1.0k
Fu-Li Xiang Canada 17 321 0.4× 524 0.7× 205 0.5× 75 0.3× 114 0.7× 29 946
Ichiro Hamanaka Japan 18 577 0.8× 496 0.7× 242 0.6× 87 0.3× 47 0.3× 26 1.1k
Tadashi Kuroda Japan 13 489 0.7× 304 0.4× 227 0.6× 138 0.5× 85 0.5× 18 956
Daigo Sawaki Japan 18 429 0.6× 411 0.6× 170 0.4× 62 0.2× 149 0.9× 43 1.1k
Antoine H. Chaanine United States 16 675 0.9× 900 1.3× 132 0.3× 42 0.2× 131 0.8× 28 1.5k

Countries citing papers authored by Peter E. Glennon

Since Specialization
Citations

This map shows the geographic impact of Peter E. Glennon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter E. Glennon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter E. Glennon more than expected).

Fields of papers citing papers by Peter E. Glennon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter E. Glennon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter E. Glennon. The network helps show where Peter E. Glennon may publish in the future.

Co-authorship network of co-authors of Peter E. Glennon

This figure shows the co-authorship network connecting the top 25 collaborators of Peter E. Glennon. A scholar is included among the top collaborators of Peter E. Glennon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter E. Glennon. Peter E. Glennon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Glennon, Peter E.. (2024). Sjögren disease, new name, new guidelines: Key messages for primary care. InnovAiT Education and inspiration for general practice. 17(11-12). 512–516.
2.
Alharbi, Hajed Obaid, Thomais Markou, Peter E. Glennon, et al.. (2022). Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice. Clinical Science. 136(22). 1661–1681. 5 indexed citations
3.
Meijles, Daniel N., Thomais Markou, Stephen J. Fuller, et al.. (2021). The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension. Clinical Science. 135(14). 1631–1647. 12 indexed citations
4.
Price, Elizabeth, Alexander Allen, Saaeha Rauz, et al.. (2020). The management of Sjögren’s syndrome: British Society for Rheumatology guideline scope. Lara D. Veeken. 60(5). 2122–2127. 5 indexed citations
5.
Glennon, Peter E.. (2011). Fibromyalgia Syndrome. InnovAiT Education and inspiration for general practice. 4(6). 332–337. 3 indexed citations
6.
Hildick‐Smith, David, Adam J. de Belder, Nina Cooter, et al.. (2010). Randomized Trial of Simple Versus Complex Drug-Eluting Stenting for Bifurcation Lesions. Circulation. 121(10). 1235–1243. 350 indexed citations
7.
Desai, Parul, et al.. (2008). Pacemaker-mediated dermatitis. EP Europace. 10(11). 1354–1354. 4 indexed citations
8.
Osman, Faizel, et al.. (2007). A simple risk score for prediction of mortality in patients undergoing percutaneous coronary intervention (PCI) for non-ST segment elevation acute coronary syndromes (NSTEACS).. PubMed. 2(4). 493–9. 2 indexed citations
9.
Glennon, Peter E., et al.. (2007). Subacute Massive Pulmonary Embolism Diagnosed by Transesophageal Echocardiography. Circulation. 116(12). e352–3. 2 indexed citations
10.
Glennon, Peter E., et al.. (1998). Tricuspid regurgitation following central line insertion in a patient undergoing haemodialysis. Postgraduate Medical Journal. 74(876). 631–632. 10 indexed citations
11.
Bogoyevitch, Marie A., Monica Andersson, Judith Brown, et al.. (1996). Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochemical Journal. 314(1). 115–121. 154 indexed citations
12.
13.
Glennon, Peter E., Melissa Petersen, & Mary N. Sheppard. (1996). Fatal giant cell myocarditis after resection of thymoma.. Heart. 75(5). 531–532. 17 indexed citations
14.
Glennon, Peter E., P H Sugden, & P.A. Poole‐Wilson. (1995). Cellular mechanisms of cardiac hypertrophy.. Heart. 73(6). 496–499. 46 indexed citations
15.
16.
Bogoyevitch, Marie A., Peter E. Glennon, Monica Andersson, et al.. (1993). Acidic fibroblast growth factor or endothelin-1 stimulate the MAP kinase cascade in cardiac myocytes. Biochemical Society Transactions. 21(4). 358S–358S. 3 indexed citations
17.
Bogoyevitch, Marie A., Peter E. Glennon, & Peter H. Sugden. (1993). Endothelin‐1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes. FEBS Letters. 317(3). 271–275. 158 indexed citations
18.
Glennon, Peter E., et al.. (1987). Metastatic melanoma of the gallbladder: A case report and review of the literature. Journal of Surgical Oncology. 34(1). 68–72. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pamela C. Powell Breakdown of academic impact, for papers by Takehiko Yamada Breakdown of academic impact, for papers by Masashi Namba Breakdown of academic impact, for papers by Daniel Walcher Breakdown of academic impact, for papers by L Simonet Breakdown of academic impact, for papers by Fu-Li Xiang Breakdown of academic impact, for papers by Ichiro Hamanaka Breakdown of academic impact, for papers by Tadashi Kuroda Breakdown of academic impact, for papers by Daigo Sawaki Breakdown of academic impact, for papers by Antoine H. Chaanine
Rankless by CCL
2026